Novel Oral Anticoagulants in Atrial Fibrillation

Prepared by Dr Hitesh Patel. Anticoagulation in patients with AF reduces stroke and mortality compared to placebo. NOACs reduce mortality compared with warfarin. In our GP symposium of 2012, we discussed the potential role of dabigatran (Pradaxa) instead of warfarin in those with atrial fibrillation (AF). Given the importance of this topic, we discussed this subject […]

Entresto – A New Treatment For Advanced Heart Failure

Prepared by Dr Selywn Wong. In patients with heart failure with reduced ejection fraction (HFrEF) ACE inhibitor therapy reduces mortality and has been the standard of care since the 1990s (ARBs may be substituted if ACE inhibitors are poorly tolerated). While beta blockers and aldosterone antagonists have further improved survival, mortality has remained high. Neprilysin […]

Beta-Blockade After MI: No Practice Should Be Set in Stone

Benefit Limited in Reperfusion Era By John M. Mandrola, MD A patient presented soon after having chest pain. The electrocardiogram (ECG) showed an ST-elevation myocardial infarction (STEMI). The day after acute percutaneous coronary intervention (PCI), cardiac enzymes met the definition of myocardial infarction (MI) but the echocardiogram showed a normal left ventricular ejection fraction (LVEF). […]

ECG Treadmill, training and support provided to TTM Hospital, Samoa

Ascot Cardiology Group Interventional Cardiologist Dr Warwick Jaffe and Nurse Mela Yudilevich travelled to Apia, Samoa this January as part of their ongoing commitment to train and support local medical staff in cardiac care. Dr Jaffe and the Ascot Cardiology Group team have continued to work closely with the Samoan Government over many years, visiting […]

Oral anticoagulation with Antiplatelet Therapy

An Update on Oral anticoagulation with Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Interventions The challenge of managing atrial fibrillation in patients who have undergone percutaneous coronary intervention for the treatment of coronary disease, is one widely shared and fraught throughout the medical field. Given the emergence of noval oral anticoagulants (NOAC) and updated current […]

Restoring the Rhythm . . . Atrial fibrillation under the scope

The global burden of atrial fibrillation remains unknown, but in New Zealand it is estimated that AF affects a minimum of five percent of the population. Atrial fibrillation is touted as the most common cardiac arrhythmia and complications can be severe – increased risk of stroke, heart failure, myocardial infarction and dementia. Management of atrial […]

Heart Failure Therapies in Focus . . . Cardiac Resynchronisation

Worldwide cardiologists and doctors alike are vested in therapies to combat heart failure and explore measures to improve the quality of life for patients – new implanted device based therapies are under active investigations- including devices that can modulate cardiac contractility, and multiple other modes to alter vagal tone. In an ever-evolving landscape of treatment […]

Heart Failure Complexities . . . A ‘black box’ of treatment measures

Around the globe, in developed countries, 1-2% of the adult population have heart failure, rising to over ten percent in those aged over 70 years. Heart failure occurs not just with reduced left ventricular ejection fraction, but also with preserved ejection fraction.– with figures steadily climbing year-on-year. However, despite the prevalence of modern-day interventions – […]